Emerging infectious diseases · 2023
Nationwide Outbreak of Candida auris Infections Driven by COVID-19 Hospitalizations, Israel, 2021-2022.
СтатьяОбзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Biran Roni, Cohen Regev, Finn Talya, Brosh-Nissimov Tal, Rahav Galia, Yahav Dafna, Amit Sharon, Shachor-Meyouhas Yael, Atamna Alaa, Bishara Jihad, Ashkenazi-Hoffnung Liat, Ben Zvi Haim, Hershman-Sarafov Mirit, Maayan Shlomo, Maor Yasmin, Schwartz Orna, Zimhony Oren, Lellouche Jonathan, Elbaz Meital, Burdelova Ela, Mizrahi Naama, Novikov Anna, Henig Oryan, Ben-Ami Ronen
Аннотация
We report an outbreak of Candida auris across multiple healthcare facilities in Israel. For the period of May 2014-May 2022, a total of 209 patients with C. auris infection or colonization were identified. The C. auris incidence rate increased 30-fold in 2021 (p = 0.00015), corresponding in time with surges of COVID-19-related hospitalization. Multilocus sequence typing revealed hospital-level outbreaks with distinct clones. A clade III clone, imported into Israel in 2016, accounted for 48.8% of typed isolates after January 2021 and was more frequently resistant to fluconazole (100% vs. 63%; p = 0.00017) and voriconazole (74% vs. 5.2%; p<0.0001) than were non-clade III isolates. A total of 23% of patients had COVID-19, and 78% received mechanical ventilation. At the hospital level, outbreaks initially involved mechanically ventilated patients in specialized COVID-19 units and then spread sequentially to ventilated non-COVID-19 patients and nonventilated patients.